Show simple item record

dc.contributor.authorCripps, AW
dc.contributor.authorPeek, K
dc.contributor.authorDunkley, M
dc.contributor.authorVento, K
dc.contributor.authorMarjason, JK
dc.contributor.authorMcIntyre, ME
dc.contributor.authorSizer, P
dc.contributor.authorCroft, D
dc.contributor.authorSedlak-Weinstein, L
dc.date.accessioned2017-05-03T14:29:34Z
dc.date.available2017-05-03T14:29:34Z
dc.date.issued2006
dc.date.modified2009-09-04T06:04:51Z
dc.identifier.issn0019-9567
dc.identifier.doi10.1128/IAI.74.2.968-974.2006
dc.identifier.urihttp://hdl.handle.net/10072/11321
dc.description.abstractThis study examines the safety and immunogenicity of an oral, whole-cell Pseudomonas aeruginosa vaccine administered to healthy volunteers. Thirty subjects received an oral dose of Pseudostat in two timed, measured doses with serological follow-up to 56 days postvaccination. Following vaccination, several individuals were identified as antibody responders for all three immunoglobulin (Ig) isotypes tested, specifically against whole-cell P. aeruginosa extract and outer membrane proteins F and I. The mean pooled lipopolysaccharide antigen-specific IgA showed the most significant and constant increases in titer postdose, with a similar increase in titer for whole-cell P. aeruginosa extract-specific IgA. The results demonstrated an increased phagocytic ability of the selected macrophage cell line in post vaccination sera. Furthermore a significant increase in intracellular macrophage killing of opsonized P. aeruginosa was also demonstrated (82% on day 14 postdose) in the presence of the postvaccination sera. The safety component of the study did not show any vaccine-attributable adverse effects in any of the subjects, as documented by clinical evidence, hematology, and biochemistry profiles. We conclude that Pseudostat is safe and immunogenic in humans at this dose and that further studies to determine the appropriate dosage and efficacy are needed. In our study, we have shown that the most significant and sustained responses to oral vaccination in human adult volunteers were serum IgA levels and that pooled sera collected postimmunization have an increased capacity to promote opsonophagocytotic killing of P. aeruginosa.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.format.extent117304 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoeng
dc.publisherAmerican Society for Microbiology
dc.publisher.placeWashington, DC
dc.publisher.urihttp://iai.asm.org/
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom968
dc.relation.ispartofpageto974
dc.relation.ispartofissue2
dc.relation.ispartofjournalInfection and Immunity
dc.relation.ispartofvolume74
dc.rights.retentionY
dc.subject.fieldofresearchBiological sciences
dc.subject.fieldofresearchAgricultural, veterinary and food sciences
dc.subject.fieldofresearchBiomedical and clinical sciences
dc.subject.fieldofresearchcode31
dc.subject.fieldofresearchcode30
dc.subject.fieldofresearchcode32
dc.titleSafety and immunogenicity of an oral inactivated whole-cell Pseudomonas aeruginosa vaccine administered to healthy human subjects.
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.rights.copyright© 2006 American Society for Microbiology. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal link for access to the definitive, published version.
gro.date.issued2006
gro.hasfulltextFull Text
gro.griffith.authorCripps, Allan W.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record